Lung Non-Squamous Non-Small Cell Cancer - docetaxel - STK11 mutation

Association details:

Biomarker:	STK11 mutation
Cancer:	Lung Non-Squamous Non-Small Cell Cancer
Drug:	docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

IASLC-WCLC 2020

Title:

P75.02-Non-Squamous NSCLC Patients Harbored STK11 or KEAP1 Mutation Showed Insensitivity to any Treatment Including Immunotherapy

Published date:

01/12/2021

Excerpt:

...we found that non-squamous NSCLC patients harbored STK11 or KEAP1 mutations had worse OS no matter treated with atezolizumab monotherapy or docetaxel (all, P < 0.001)….Non-squamous NSCLC patients harbored STK11 or KEAP1 mutation were not sensitive to any treatment, suggesting they may be a special subtype.